Clinical Research Directory

Inclusion Criteria: 1. Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed. 2. Subjects have received prior systemic therapy in sponsor-initiated clinical trials of cadonilimab (AK104), and this extension study is conducted after the completion of the original trial. 3. Agree to proceed with the extended follow-up procedures. 4. This is an observational and non-interventional clinical study, in which subjects are allowed to participate in other clinical studies at the same time. Exclusion Criteria: * None